CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Thelial Technologies is developing a drug for Eosinophilic Esophagitis using a unique fly embryo-based technology to discover compounds that modulate cell polarity. This targeted treatment aims to alleviate symptoms and improve patient outcomes for a condition currently lacking effective therapies.
Thelial Technologies, S.A. is a revenue generating drug discovery company that applies its unique, proprietary fly embryo-based technology to find new candidate compounds for the treatment of diseases that can be addressed by cell polarity modulation.
By modulating cell polarity it is possible to specifically target a series of indications, where reduced integrity of epithelial cellular barriers is a key to pathologies.
Using Thelial’s patented discovery platform theLiTETM the company has identi…
THELIAL TECHNOLOGIES SA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
